Feb. 2 at 3:03 PM
60 Degrees Pharmaceuticals announced a partnership with GoodRx to offer prescription savings on ARAKODA, its FDA-approved, once-weekly malaria prevention drug. Under the agreement, eligible consumers will be able to save up to 30% on ARAKODA (tafenoquine) through the GoodRx platform at more than 70,000 U.S. pharmacies, or via home delivery when available, starting February 2, 2026.
ARAKODA is primarily prescribed for travelers to malaria-endemic regions and is currently the only FDA-approved weekly prescription option for malaria prevention in the U.S. The drug, approved in 2018 and originally developed by the Walter Reed Army Institute of Research, has a long terminal half-life of about 16 days, allowing for less frequent dosing compared with other prophylactic treatments. Despite the potential boost to accessibility from the GoodRx partnership, shares moved lower in early trading following the announcement.
$SXTP $GDRX